Wave Life Sciences, a preclinical biotech developing a nucleic acid therapy platform, announced terms for its IPO on Monday.
The Singapore-based company plans to raise $80 million by offering 5.0 million shares at a price range of $15 to $17. At the midpoint of the proposed range, Wave Life Sciences would command a fully diluted market value of $402 million.
Wave Life Sciences, which was founded in 2012, plans to list on the Nasdaq under the symbol WVE. Jefferies and Leerink Partners are the joint bookrunners on the deal. It is expected to price during the week of November 9, 2015.
